HRP20171898T1 - Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika - Google Patents

Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika Download PDF

Info

Publication number
HRP20171898T1
HRP20171898T1 HRP20171898TT HRP20171898T HRP20171898T1 HR P20171898 T1 HRP20171898 T1 HR P20171898T1 HR P20171898T T HRP20171898T T HR P20171898TT HR P20171898 T HRP20171898 T HR P20171898T HR P20171898 T1 HRP20171898 T1 HR P20171898T1
Authority
HR
Croatia
Prior art keywords
ribavirin
combination
daas
patient
use according
Prior art date
Application number
HRP20171898TT
Other languages
English (en)
Croatian (hr)
Inventor
Barry M. Bernstein
Sandeep Dutta
Wei Liu
Thomas J. PODSADECKI
Andrew L. Campbell
Rajeev M. Menon
Chih-Wei Lin
Tianli WANG
Walid M. Awni
Sven MENSING
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171898(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of HRP20171898T1 publication Critical patent/HRP20171898T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20171898TT 2013-03-14 2014-03-14 Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika HRP20171898T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14
EP14725812.3A EP2968302B9 (en) 2013-03-14 2014-03-14 Combination of direct acting antiviral agents and ribavirin for treating hcv patients
PCT/US2014/027556 WO2014152635A1 (en) 2013-03-14 2014-03-14 Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Publications (1)

Publication Number Publication Date
HRP20171898T1 true HRP20171898T1 (hr) 2018-04-06

Family

ID=50771575

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171898TT HRP20171898T1 (hr) 2013-03-14 2014-03-14 Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika

Country Status (28)

Country Link
US (1) US20140274934A1 (enExample)
EP (4) EP3318258B1 (enExample)
JP (3) JP6563894B2 (enExample)
KR (2) KR20180045055A (enExample)
CN (3) CN109908353A (enExample)
AU (3) AU2014239322B2 (enExample)
BR (1) BR112015020918A2 (enExample)
CA (1) CA2901818C (enExample)
CY (1) CY1121474T1 (enExample)
DK (1) DK2968302T3 (enExample)
EA (2) EA030482B1 (enExample)
ES (1) ES2654109T3 (enExample)
HK (1) HK1255257A1 (enExample)
HR (1) HRP20171898T1 (enExample)
HU (1) HUE036069T2 (enExample)
IL (2) IL240445B (enExample)
LT (1) LT2968302T (enExample)
MX (1) MX2015012536A (enExample)
NO (1) NO3090119T3 (enExample)
PL (1) PL2968302T4 (enExample)
PT (1) PT2968302T (enExample)
RS (1) RS56735B1 (enExample)
SG (2) SG11201507361YA (enExample)
SI (1) SI2968302T1 (enExample)
SM (1) SMT201800017T1 (enExample)
TW (2) TWI678205B (enExample)
WO (1) WO2014152635A1 (enExample)
ZA (1) ZA201705080B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3318258B1 (en) 2013-03-14 2020-05-13 AbbVie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients
CN105658219A (zh) * 2013-10-25 2016-06-08 艾伯维公司 用于治疗hcv的方法
US20150174194A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
CA2943054A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
EP3383662B1 (en) 2016-01-08 2020-09-02 Entrust Datacard Corporation Card printing mechanism with card return path
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
MA46292A (fr) * 2016-09-23 2019-07-31 Abbvie Inc Réglage de dose
CA2994496A1 (en) * 2017-02-14 2018-08-14 Abbvie Inc. Methods for treating hcv
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
CN112351799A (zh) * 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522862A (ja) * 2008-06-10 2011-08-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EP2853531A3 (en) * 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
TWI523658B (zh) * 2010-09-21 2016-03-01 安塔製藥公司 巨環脯胺酸衍生之ｈｃｖ絲胺酸蛋白酶抑制劑
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
EP3318258B1 (en) 2013-03-14 2020-05-13 AbbVie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Also Published As

Publication number Publication date
JP6563894B2 (ja) 2019-08-21
CY1121474T1 (el) 2020-05-29
PL2968302T3 (pl) 2018-04-30
WO2014152635A9 (en) 2014-12-11
EP3318258B1 (en) 2020-05-13
CA2901818C (en) 2021-05-04
EP2968302A1 (en) 2016-01-20
LT2968302T (lt) 2017-12-27
EP3733180A1 (en) 2020-11-04
IL267927A (en) 2019-09-26
SG11201507361YA (en) 2015-10-29
SG10201709840UA (en) 2018-01-30
WO2014152635A1 (en) 2014-09-25
EP2968302B1 (en) 2017-09-06
TW202002979A (zh) 2020-01-16
CN109908353A (zh) 2019-06-21
DK2968302T3 (en) 2017-12-18
ZA201705080B (en) 2019-02-27
PT2968302T (pt) 2018-01-03
TWI678205B (zh) 2019-12-01
EA201890507A1 (ru) 2018-07-31
MX2015012536A (es) 2016-01-12
HUE036069T2 (hu) 2018-06-28
CN108187056A (zh) 2018-06-22
CN105007921B (zh) 2018-12-11
KR20180045055A (ko) 2018-05-03
JP2019167347A (ja) 2019-10-03
NO3090119T3 (enExample) 2018-03-31
HK1213191A1 (en) 2016-06-30
EA030482B1 (ru) 2018-08-31
US20140274934A1 (en) 2014-09-18
JP2019214585A (ja) 2019-12-19
AU2018202581A1 (en) 2018-05-10
AU2020201656A1 (en) 2020-03-26
RS56735B1 (sr) 2018-03-30
BR112015020918A2 (pt) 2017-07-18
IL240445A0 (en) 2015-09-24
JP2016513703A (ja) 2016-05-16
AU2014239322A1 (en) 2015-08-27
SMT201800017T1 (it) 2018-03-08
IL240445B (en) 2019-07-31
KR101853605B1 (ko) 2018-05-03
EA201591701A1 (ru) 2016-02-29
EP3318258A1 (en) 2018-05-09
CN105007921A (zh) 2015-10-28
PL2968302T4 (pl) 2018-04-30
TW201505633A (zh) 2015-02-16
KR20150129035A (ko) 2015-11-18
CA2901818A1 (en) 2014-09-25
AU2014239322B2 (en) 2018-04-05
SI2968302T1 (en) 2018-04-30
AU2018202581B2 (en) 2019-12-05
EP3915559A1 (en) 2021-12-01
EP2968302B9 (en) 2019-02-13
ES2654109T3 (es) 2018-02-12
HK1255257A1 (en) 2019-08-09

Similar Documents

Publication Publication Date Title
HRP20171036T1 (hr) Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c
JP2014530874A5 (enExample)
SI2968302T1 (en) Combination of directly-acting antiviral agents and ribavarin for the treatment of patients with HCV
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
JP2016513703A5 (enExample)
HK1199816A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
HRP20180237T4 (hr) Metode za liječenje hcv-a
RU2015114543A (ru) Способы лечения гепатита с
RU2019114665A (ru) Противовирусные композиции для лечения инфекций, связанных с коронавирусами
RU2013119607A (ru) Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
HRP20241221T1 (hr) POLICIKLIČNI KARBAMOILPIRIDONSKI DERIVATI ZA LIJEČENJE HIV-a
HRP20110713T1 (hr) Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
RU2012136824A (ru) Способы лечения вирусной инфекции гепатита с
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
MX2018000240A (es) Metodos para tratar el vhc.
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
RU2013105504A (ru) Лекарственное средство для предотвращения и/или лечения гепатоклеточной карциномы
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
RU2013120345A (ru) Новые способы лечения инфекции, вызванной вирусом гепатита с
EA201692514A1 (ru) Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
EA201491652A1 (ru) Средство для лечения вирусного гепатита с